<DOC>
	<DOC>NCT02305277</DOC>
	<brief_summary>Single-centre, open-label, randomised, three-part, two-way crossover study in 84 healthy volunteers. In each part, the study consisted of two consecutive single-dose treatment periods separated by a washout period of at least 14 days.</brief_summary>
	<brief_title>Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Opicapone</mesh_term>
	<criteria>A signed and dated informed consent form before any studyspecific screening procedure was performed; Male or female subjects aged 18 to 45 years, inclusive; Body mass index (BMI) between 18 and 30 kg/m2 inclusive; Healthy as determined by prestudy medical history, physical examination, vital signs, complete neurological examination and 12lead electrocardiogram (ECG); Negative tests for hepatitis B surface antigen (HBsAg), anti hepatitis C virus antibodies (HCV Ab) and antihuman immunodeficiency virus antibodies (HIV1 and HIV2 Ab) at screening; Clinical laboratory test results clinically acceptable at screening and admission to each treatment period; Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period; Nonsmokers or exsmokers for at least 3 months; Able to participate, and willing to give written informed consent and comply with the study restrictions. If female: She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used an effective nonhormonal method of contraception [intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical or vault caps) with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he was the sole partner of that subject] for all the duration of the study; She had a negative serum pregnancy test at screening and a negative urine pregnancy test at admission to each treatment period. Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders, or had a clinically relevant surgical history; Had clinically relevant findings in laboratory tests, particularly any abnormality in the coagulation tests, or any abnormality in the liver function tests; Had a history of relevant atopy or drug hypersensitivity; Had a history of alcoholism and/or drug abuse; Consumed more than 14 units of alcohol per week [1 unit of alcohol = 280 mL beer (34°) = 100 mL wine (1012°) = 30 mL spirits (40°)]; Had a significant infection or known inflammatory process on screening or admission to each treatment period; Had acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period; Had used medicines within 2 weeks of admission to first period that could affect the safety or other study assessments, in the Investigator's opinion; Had previously received opicapone; Had used any investigational drug or participated in any clinical trial within 90 days prior to screening; Had participated in more than 2 clinical trials within the 12 months prior to screening; Had donated or received any blood or blood products within the 3 months prior to screening; Were vegetarians, vegans or had medical dietary restrictions; Could not communicate reliably with the Investigator; Were unlikely to cooperate with the requirements of the study; Were unwilling or unable to give written informed consent; If female: She was pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>